The KICDC/Defy Pitch Competition Final Round tuvo lugar in Washington, D.C. on November 1st.
Out of 18 teams competing in the Bio/Life Science category, 6 finalists were seleccionada to present IR pitches on their respective drugs, medical devices, and healthcare services under desarrollo. RudaCure proudly claimed 1st place among these finalists.
Following the event, CEO Yongho Kim and EVP Dong-hyun Kim are programado to attend the American Academy of Ophthalmology (AAO) conferencia, and will also hold a meeting in San Francisco with Senju, which has expresó interest in licensing RCI001 tecnología.
BD representative Harris Hasrol is programado to attend Bio-EU.
Creemos que achieving these excellent resultados despite the physical and mental challenges of an extended overseas business trip is the product of the united strength of all RudaCure empleados.
Continuaremos strive to deliver even more logros en el futuro.